Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the opdivo (nivolumab) market right now?

The market size for opdivo (nivolumab) has been witnessing robust growth in the recent period. The market is forecasted to surge from a value of $7,709.49 million in 2024 to reach $8,335.54 million in 2025, representing a promising compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historical period include an increased prevalence of cancer, higher spending in R&D capabilities, more investments in healthcare infrastructures, a rise in cases of non-small lung cancer, and a boost in healthcare spending on capital equipment.

How fast Is the opdivo (nivolumab) market expected to grow, and what’s its future value?

The market size for opdivo (nivolumab) is predicted to experience robust expansion in the coming years, reaching $11,281.56 million in 2029, recording a compound annual growth rate (CAGR) of 7.9%. The anticipated growth during the forecast period is due to the rising adoption of immunotherapy, increased knowledge about immunotherapy and its advantages, escalated healthcare spending on capital equipment, expanded use of nivolumab for various indications, and a heightened preference for immunotherapy treatments. Key trends expected during the forecast period comprise product innovation, entry into new geographical markets, ongoing clinical trials, amplifying trend of personalized medicine, and progress in cancer research.

Get your opdivo (nivolumab) market report here!

https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-

What are the leading drivers of growth in the opdivo (nivolumab) market?

The opdivo (nivolumab) market is predicted to thrive due to the rising prevalence of non-small lung cancer. Accounting for approximately 85% of all lung cancer instances, non-small cell lung cancer (NSCLC) is the most prevalent kind. This growth in NSCLC cases can be traced back to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a history of cancer in the family. Opdivo functions by obstructing the PD-1 receptor on immune cells, thus amplifying the body’s immune response to recognize and combat cancer cells. The American Cancer Society, based in the United States, reported in 2024 that 234,580 new cases of lung cancer were identified in the US, with 80% of them being NSCLC. This signifies an incline compared to 2023’s 238,340 lung cancer diagnoses. Hence, the surge in non-small lung cancer cases is accelerating the rise of the opdivo (nivolumab) market.

What are the key segments defining the opdivo (nivolumab) market?

The opdivo (nivolumab)market covered in this report is segmented –

1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL

2) By Dosage: Injection; Solution; Other Dosages

3) By Demographic: Adult; Pediatric

4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications

5) By End-User: Hospitals; Clinics; Other End Users

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp

Who are the key players steering the development of the opdivo (nivolumab) market?

Major companies operating in the opdivo (nivolumab) market include Bristol-Myers Squibb, Ono Pharmaceutical

What emerging trends are influencing the growth of the opdivo (nivolumab) market?

One key trend observed in the Opdivo (nivolumab) market involves the advancement of combination therapies with the aim of heightened efficacy and broadened application across various forms of cancer. Such combination strategies are developed to overcome resistance mechanisms, offering a more thorough treatment alternative for late-stage cancer patients. For example, in October 2024, the US-based federal institute, the Food and Drug Administration, granted its approval for the use of Opdivo (nivolumab) in tandem with platinum-doublet chemotherapy. The approval was for neoadjuvant treatment, followed by the use of single-agent nivolumab after surgery as adjuvant treatment, specifically meant for adults who have resectable non-small cell lung cancer without known EGFR or ALK mutations. This allows for the use of Opdivo before surgery in combination with platinum-doublet chemotherapy and as a solo treatment post-surgery.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19914

Which regions are most influential in expanding the opdivo (nivolumab) market?

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Protein Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-assays-global-market-report

Therapeutic Proteins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Kidney Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: